News | 100 million Covid-19 vaccinations by Enlivio Health (formerly Optum | EMIS) software

Enlivio Health (formerly Optum | EMIS) has now recorded over 100 million Covid-19 vaccinations in England through its Outcomes4Health software.

Enlivio was the first UK health-tech provider to launch a clinical software system that could support the NHS in mobilising the largest vaccination programme in its history.

With 116 million doses administered in England so far, Enlivio has supported just over 86 per cent of all vaccinations.

Dr Shaun O'Hanlon, former CEO at Enlivio, said: "We are proud to have supported the biggest vaccination programme in NHS history.

"Supporting the NHS is one of the things Optum [now Enlivio Health] does best and just over a year ago we pulled together with the NHS to get the technology ready in record time."

Dr Shaun O’Hanlon
Former CEO at Enlivio

"Reaching over 100 million vaccinations in a little over a year is incredible, and we continue to support the programme through the deployment of the booster drive."

For the first seven months of the programme Enlivio remained the only provider of the technology needed to drive and record vaccinations within GP practices, pharmacies and mass vaccination centres across England.

The software, which was delivered within an impressive eight-week timeframe and continues to evolve through the roll-out of the booster vaccination drive, was built using the IT system Outcomes4Health.

Outcomes4Health was developed by Pinnacle, a company acquired by Enlivio in early 2020 to record clinical services provided by community pharmacies, including the annual flu vaccination programme.

For each of the 100 million vaccinations recorded to date through Outcomes4Health, the patient record is collated and shared through interoperability to the National Immunisation Management System (NIMS) and GP clinical systems within a matter of hours. It then appears for patients to see via the NHS app and Patient Access.

In addition to helping mobilise the Covid-19 vaccination programme, Enlivio also played a vitally important role in the research which identified the 1.5 million people most at risk from the disease and who should be prioritised for early vaccination. This research also raised public awareness of key Covid-19 risk factors such as age, ethnicity and body mass index, as well as certain medical conditions and treatments.

Through Outcomes4Health Enlivio also helped to administer over 2.2m flu vaccinations in England during 2020.